Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis
Yibo Fan, Xiaofang Che, Jinglei Qu, et al.
Annals of Surgical Oncology (2019) Vol. 26, Iss. 11, pp. 3745-3755
Closed Access | Times Cited: 157

Showing 26-50 of 157 citing articles:

Exosomes: Key Messengers Mediating the Interaction Between Tumor Cells and CD8+ T Cells in the Tumor Microenvironment
Yilin Li, Qiwei Yang, Danni Li, et al.
International Journal of Nanomedicine (2025) Vol. Volume 20, pp. 653-667
Open Access | Times Cited: 1
The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer
Yanyan Tang, Ping Zhang, Yumin Wang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 66
Modulating Cytokine Production via Select Packaging and Secretion From Extracellular Vesicles
Betsy Barnes, Carter Somerville
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 62
Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
Chaoxu Zhang, Yibo Fan, Xiaofang Che, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 55
Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial
Eugene Shenderov, Karim Boudadi, Wei Fu, et al.
The Prostate (2021) Vol. 81, Iss. 6, pp. 326-338
Open Access | Times Cited: 55
PDL1‐positive exosomes suppress antitumor immunity by inducing tumor‐specific CD8+ T cell exhaustion during metastasis
Ji Chen, Yang Song, Feng Miao, et al.
Cancer Science (2021) Vol. 112, Iss. 9, pp. 3437-3454
Open Access | Times Cited: 51
Extracellular vesicles containing PD-L1 contribute to CD8+ T-cell immune suppression and predict poor outcomes in small cell lung cancer
Xiaoyan Dou, Yan Hua, Zhaowu Chen, et al.
Clinical & Experimental Immunology (2022) Vol. 207, Iss. 3, pp. 307-317
Open Access | Times Cited: 35
The Role of Extracellular Vesicles in Metabolic Reprogramming of the Tumor Microenvironment
Eran Fridman, Lana Ginini, Ziv Gil
Cells (2022) Vol. 11, Iss. 9, pp. 1433-1433
Open Access | Times Cited: 35
Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies
Jiaxing Liu, Xueqiang Peng, Shuo Yang, et al.
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 33
PD-1/PD-L1 axis in organ fibrosis
Youliang Zhao, Yaqian Qu, Changfu Hao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21
Exosomal PD-L1 derived from head and neck squamous cell carcinoma promotes immune evasion by activating the positive feedback loop of activated regulatory T cell-M2 macrophage
Fanqin Wei, Ruihua Fang, Kexing Lyu, et al.
Oral Oncology (2023) Vol. 145, pp. 106532-106532
Closed Access | Times Cited: 19
Exosome nanovesicles as potential biomarkers and immune checkpoint signaling modulators in lung cancer microenvironment: recent advances and emerging concepts
Naushad Ahmad Khan, Mohammad Asim, Kabir H. Biswas, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 19
Hyperprogression of cutaneous T cell lymphoma after anti–PD-1 treatment
Yumei Gao, Simeng Hu, Ruoyan Li, et al.
JCI Insight (2023) Vol. 8, Iss. 4
Open Access | Times Cited: 18
Helicobacter pylori CagA promotes immune evasion of gastric cancer by upregulating PD-L1 level in exosomes
Jinfeng Wang, Rilin Deng, Shuai Chen, et al.
iScience (2023) Vol. 26, Iss. 12, pp. 108414-108414
Open Access | Times Cited: 18
A key driver to promote HCC: Cellular crosstalk in tumor microenvironment
Pengyue Liu, Kong Lingyu, Ying Liu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 17
Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer
Yinjun He, Xiang Zhang, Ming Zhu, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 16
PD-1/CD80+ small extracellular vesicles from immunocytes induce cold tumours featured with enhanced adaptive immunosuppression
Lin‐Zhou Zhang, Jiegang Yang, Gaili Chen, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery
Ningqiang Gong, Wenqun Zhong, Mohamad‐Gabriel Alameh, et al.
Nature Materials (2024)
Closed Access | Times Cited: 7
Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas
Kunihiro Asanuma, Tomoki Nakamura, Akinobu Hayashi, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 47
Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy
Elena Shklovskaya, Helen Rizos
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 19, pp. 7139-7139
Open Access | Times Cited: 47
5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients
Min Zhang, Yibo Fan, Xiaofang Che, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 46
Extracellular vesicles and oncogenic signaling
Antonia Schubert, Michael Boutros
Molecular Oncology (2020) Vol. 15, Iss. 1, pp. 3-26
Open Access | Times Cited: 45
Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
Jacob J. Orme, Elizabeth Ann L. Enninga, Fabrice Lucien-Matteoni, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001113-e001113
Open Access | Times Cited: 44
Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy
Sergio Ayala‐Mar, Javier Donoso‐Quezada, José González‐Valdez
Journal of Immunology Research (2021) Vol. 2021, pp. 1-18
Open Access | Times Cited: 40
The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target
Lingxiao Ye, Zhengxin Zhu, Xiaochuan Chen, et al.
Cells (2021) Vol. 10, Iss. 11, pp. 3247-3247
Open Access | Times Cited: 38

Scroll to top